방사선 치료 시장 : 예측(2025-2030년)

The Radiotherapy Market is expected to grow from USD 7.038 billion in 2025 to USD 8.997 billion in 2030, at a CAGR of 5.03%.

The Radiotherapy Market is a critical component of global cancer care, delivering targeted radiation to eradicate cancerous cells while sparing healthy tissues. Utilized in over 50% of cancer cases worldwide, radiotherapy is a cornerstone treatment, often combined with surgery or chemotherapy. The market is driven by rising cancer prevalence, technological advancements, and increasing healthcare investments, particularly in Asia-Pacific, North America, and Europe. Despite challenges such as high costs and professional shortages, the market is poised for robust growth through 2030, fueled by innovations in precision radiotherapy and expanding oncology infrastructure.

Market Overview

Radiotherapy employs ionizing radiation to target malignant cells, offering non-invasive or minimally invasive treatment for cancers like prostate, breast, lung, and head and neck. External beam radiotherapy (EBRT) uses linear accelerators for versatile applications, while brachytherapy targets localized cancers like prostate and cervical. Systemic radiotherapy, using radioactive drugs, addresses cancers such as thyroid. Hospitals dominate as end-users, managing complex cases, while ambulatory surgical centers handle outpatient procedures. In 2025, the market reflects a growing global cancer burden, with 19.3 million new diagnoses reported in 2020 and projections for significant increases by 2030 (World Health Organization, 2020). Innovations like AI and machine learning in treatment planning enhance precision, particularly for EBRT and brachytherapy, supporting market expansion.

Growth Drivers

Key factors driving the Radiotherapy Market include:

• Rising Cancer Prevalence: With a projected rise in global cancer cases, demand for radiotherapy is increasing significantly.
• Technological Advancements: Innovations like image-guided radiotherapy (IGRT) and stereotactic body radiotherapy (SBRT) improve outcomes. In March 2024, Varian launched the Halcyon 3.0 system, enhancing image-guided precision (Siemens Healthineers, 2024). In April 2024, Elekta introduced the Harmony Pro for prostate cancer treatment (Elekta AB, 2024).
• Healthcare Investments: Governments are expanding oncology infrastructure. India allocated $1.2 billion to cancer care in 2024 (Ministry of Health and Family Welfare, 2024), while Japan invested $1 billion in proton therapy centers (Japanese Ministry of Health, 2024).
• Aging Population: In 2024, 10% of the global population was over 65, driving higher cancer incidence and radiotherapy demand (United Nations, 2024).

Market Restraints

Challenges include:

• High Costs: Advanced systems like proton therapy units are expensive, limiting access in low-resource regions.
• Side Effects: Radiation-related issues like fatigue and skin damage deter some patients.
• Professional Shortages: A global lack of trained oncologists and technicians impacts service delivery.

Geographical Analysis

• North America: The region leads the market, driven by advanced healthcare infrastructure and 1.9 million new cancer cases in the U.S. in 2024 (American Cancer Society, 2024). Hospitals dominate, with 80% of treatments using EBRT. The U.S. healthcare expenditure reached $4.5 trillion, and the FDA approved 15 new radiotherapy devices in 2024 (U.S. Food and Drug Administration, 2024). Canada invested $500 million in cancer care, while Mexico's oncology facilities grew by 10% (Canadian Cancer Society, 2024; Mexican Ministry of Health, 2024).
• Asia-Pacific: The fastest-growing region, led by China's 4.8 million cancer cases and India's 8% cancer burden increase in 2024 (National Cancer Center of China, 2024; Ministry of Health and Family Welfare, 2024). Hospitals account for 90% of treatments, with EBRT used in 65% of cases. Japan and South Korea advance through proton therapy and AI-integrated systems, with Japan investing $1 billion in 2024 (Japanese Ministry of Health, 2024).
• Europe: Germany and the UK drive growth, with Germany reporting 500,000 new cancer cases in 2024 (German Cancer Research Center, 2024). Hospitals deliver 85% of treatments, primarily EBRT. France invested €1.5 billion in oncology, and the EU allocated €4 billion for cancer research in 2024 (French Ministry of Health, 2024; European Commission, 2024).

Segment Analysis

• External Beam Radiotherapy (EBRT): The largest segment, used in 70% of global treatments in 2024, benefits from systems like Varian's Halcyon 3.0 and Accuray's CyberKnife S7, upgraded in January 2024 (Accuray Incorporated, 2024). Its versatility and AI integration drive growth.
• Prostate Cancer: A key application, with 250,000 U.S. cases in 2024, benefits from EBRT and brachytherapy, enhanced by Elekta's Harmony Pro (American Cancer Society, 2024; Elekta AB, 2024).
• Hospitals: Dominating end-users, hospitals handle 80% of treatments, supported by advanced infrastructure and investments like the UK's £500 million cancer fund (UK Department of Health, 2024).

Key Developments

• Varian Halcyon 3.0: Launched in March 2024, enhancing EBRT precision (Siemens Healthineers, 2024).
• Elekta Harmony Pro: Introduced in April 2024, optimized for prostate cancer (Elekta AB, 2024).
• Accuray CyberKnife S7 Upgrade: Improved SBRT delivery in January 2024 (Accuray Incorporated, 2024).
• Regional Investments: India ($1.2 billion), Japan ($1 billion), EU (€4 billion), and U.S. (15 FDA approvals) in 2024 bolster market growth.

The Radiotherapy Market is thriving, driven by rising cancer rates, technological advancements, and healthcare investments. North America leads, with Asia-Pacific growing rapidly. Industry experts should focus on innovation, regulatory compliance, and regional trends to leverage opportunities through 2030.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Radiotherapy Market Segmentation:

By Offering

• Hardware
• Software & Services

By Type

• Internal Radiation Therapy
• External Radiation Therapy
• 3D-Conformal Radiation Therapy (3D-CRT)
• Intensity-Modulated Radiation Therapy (IMRT)
• Image Guided Radiotherapy (IGRT)
• Others

By Application

• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Head & Neck Cancer
• Others

By End-User

• Hospital
• Ambulatory Surgical Center
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. RADIOTHERAPY MARKET BY OFFERING

• 5.1. Introduction
• 5.2. Hardware
• 5.3. Software & Services

6. RADIOTHERAPY MARKET BY TYPE

• 6.1. Introduction
• 6.2. Internal Radiation Therapy
• 6.3. External Radiation Therapy
  • 6.3.1. 3D-Conformal Radiation Therapy (3D-CRT)
  • 6.3.2. Intensity-Modulated Radiation Therapy (IMRT)
  • 6.3.3. Image Guided Radiotherapy (IGRT)
  • 6.3.4. Others

7. RADIOTHERAPY MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Prostate Cancer
• 7.3. Breast Cancer
• 7.4. Lung Cancer
• 7.5. Head & Neck Cancer
• 7.6. Others

8. RADIOTHERAPY MARKET BY END-USER

• 8.1. Introduction
• 8.2. Hospital
• 8.3. Ambulatory Surgical Center
• 8.4. Others

9. RADIOTHERAPY MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. Germany
  • 9.4.2. France
  • 9.4.3. United Kingdom
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Israel
  • 9.5.4. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. India
  • 9.6.3. Japan
  • 9.6.4. South Korea
  • 9.6.5. Indonesia
  • 9.6.6. Thailand
  • 9.6.7. Taiwan
  • 9.6.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Elekta AB
• 11.2. Accuray Incorporated
• 11.3. Ion Beam Applications Group
• 11.4. Canon Medical Systems Corporation
• 11.5. Mirada Medical
• 11.6. Eckert & Ziegler
• 11.7. Siemens Healthineers
• 11.8. Mevion Medical Systems, Inc.
• 11.9. ALCEN (PMB)
• 11.10. CQ Medical

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key benefits for the stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations